Seguimento clínico a médio prazo com uso exclusivo de enxertos arteriais na revascularização completa do miocárdio em pacientes com doença coronária triarterial Method: Between July 1995 and July 1997, 137 consecutive patients with triple vessel coronary atherosclerotic disease underwent complete coronary artery bypass grafting exclusively using arterial grafts. Of these patients, 112 (81.7%) were male, with ages ranging from 36 to 78 years old (mean 56.5 years). Three hundred and sixty-three arterial grafts were used to perform 442 coronary anastomoses, an average of 3.2 coronary anastomoses per patient. The arterial grafts used were left internal thoracic artery (99.3%), right internal thoracic artery (56.2%), radial artery (94.9%), right gastroepiploic artery (13.9%) and inferior epigastric artery (0.7%). In 80 (58.4%) patients, arterial composite "Y" grafts were constructed with the left internal thoracic artery and another arterial graft.Results: No operative deaths occurred. Four (2.9%) deaths occurred in the postoperative period and only one (0.7%) patient needed reoperation in the immediate follow-up. The 7-year actuarial survival was 94.0% and the event free probability (myocardial infarction, angioplasty, reoperation or death) was 87.0%.Conclusions: Good early and midterm clinical follow-ups can be achieved by exclusively using arterial grafts in the complete coronary artery bypass grafting of patients with triple vessel coronary arteriosclerotic disease. A long-term follow-up will be necessary to show the influence of exclusive use of arterial grafts in the surgical treatment of coronary insufficiency.Descriptors: Miyocardial revascularization. Mammary arteries. Arteriosclerosis.
ResumoObjetivo: Avaliar os benefícios a médio prazo do uso exclusivo de enxertos arteriais em pacientes com doença aterosclerótica coronária triarterial submetidos à revascularização completa do miocárdio.
10LISBOA, LAF ET AL -Midterm follow-up with exclusive use of arterial grafts in complete myocardial revascularization of patients with triple vessel coronary artery disease
Rev